Yarrow Bioscience raises $150M as AbbVie reports positive menstrual migraine trial results
read at Endpoints ↗Positive readoutPositive
Yarrow Bioscience, based in New Haven, announced pricing of a $150 million equity offering at $26 per share, roughly $2.50 below the previous closing price.
The capital raise will provide additional funding for the company's ongoing research and development programs.
In separate news, AbbVie reported that its experimental therapy for menstrual migraine met its primary endpoints in a recent trial, indicating potential efficacy for the condition.
The brief also referenced upcoming updates from Sino Biopharm and AtomVie, though no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial”
read at Endpoints ↗77 words · retrieved Sep 11
comments(0)
5-min edit window · permanent after that